st report 11

7/31/2019 ST REPORT 11

1/23

The Indian pharmaceutical industry is a success story providing employment for millions and

ensuring that essential drugs at affordable prices are available to the vast population of this sub-

continent.Richard Gerster

The Indian Pharmaceutical Industrytoday is in the front rank of Indias science-basedindustries with wide ranging capabilities in the complex field of drug manufacture andtechnology. It ranks very high in the third world, in terms of technology, quality and range ofmedicines manufactured. From simple headache pills to sophisticated antibiotics and complexcardiac compounds, almost every type of medicine is now made indigenously.

Playing a key role in promoting and sustaining development in the vital field of medicines,Indian Pharma Industry boasts of quality producers and many units approved by regulatoryauthorities in USA and UK. International companies associated with this sector have stimulated,assisted and spearheaded this dynamic development in the past 53 years and helped to put Indiaon the pharmaceutical map of the world.

Growth Scenario in 2010

India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rankis 14th in terms of value. Between September 2008 and September 2009, the total turnover ofIndia's pharmaceuticals industry was US$ 21.04 billion. The domestic market was worth US$12.26 billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicalsand Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reachedUS$ 10.04 billion in size in July 2010. A highly organized sector, the Indian Pharma Industry isestimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. Know more out thisin our article onIndian Pharmaceutical Industry- Future TrendsAlso check outPharmaceutical

Market Trends 2010

Leading Pharmaceutical Companies

In the domestic market, Cipla retained its leadership position with 5.27 per cent share. Ranbaxyfollowed next. The highest growth was for Mankind Pharma (37.2%). Other leading companiesin the Indian pharma market in 2010 are:

Sun Pharma (25.7%) Abbott (25%) Zydus Cadila (24.1%) Alkem Laboratories (23.3%) Pfizer (23.6 %) GSK India (19%) Piramal Healthcare (18.6 %) Lupin (18.8 %)

For details check outList of Top 10 Pharmaceutical Companies in India
http://www.pharmaceutical-drug-manufacturers.com/articles/indian-pharmaceutical-industry.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/indian-pharmaceutical-industry.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/indian-pharmaceutical-industry.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/top-10-pharmaceutical-companies-in-india.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/top-10-pharmaceutical-companies-in-india.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/top-10-pharmaceutical-companies-in-india.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/top-10-pharmaceutical-companies-in-india.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/indian-pharmaceutical-industry.html

7/31/2019 ST REPORT 11

2/23

Future Prospects

The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6billion in 2009. This was stated in a report title "India Pharma 2020: Propelling access andacceptance, realising true potential" by McKinsey & Company. In the same report, it was also

mentioned that in an aggressive growth scenario, the pharma market has the further potential toreach US$ 70 billion by 2020

Due to increase in the population of high income group, there is every likelihood that they willopen a potential US$ 8 billion market for multinational companies selling costly drugs by 2015.This was estimated in a report by Ernst & Young. The domestic pharma market is estimated totouch US$ 20 billion by 2015. The healthcare market in India to reach US$ 31.59 billion by2020. The sale of all types ofpharmaceutical drugsand medicines in the country stands at US$9.61 billion, which is expected to reach around US$ 19.22 billion by 2012. Thus India wouldreally become a lucrative destination for clinical trials for global giants.

There was another report by RNCOS titled "Booming Pharma Sector in India" in which it wasprojectedt that thepharmaceutical formulationsindustry is expected to prosper in the samemanner as the pharmaceutical industry. The domestic formulations market will grow at an annualrate of around 17% in 2010-11, owing to increasing middle class population and rapidurbanisation. Read More inFuture Prospects of Indian Pharma Industry.

Characteristics of Indian Pharmaceutical Industry

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. Ithas expanded drastically in the last two decades. The leading 250 pharmaceutical companiescontrol 70% of the market with market leader holding nearly 7% of the market share. It is an

extremely fragmented market with severe price competition and government price control.

The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs,drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals andinjectibles. There are about 250 large units and about 8000 Small Scale Units, which form thecore of the pharmaceutical industry in India (including 5 Central Public Sector Units). Theseunits produce the complete range of pharmaceutical formulations, i.e., medicines ready forconsumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value andused for production of pharmaceutical formulations.

Following the de-licensing of the pharmaceutical industry, industrial licensing for most of the

drugs and pharmaceutical products has been done away with. Manufacturers are free to produceany drug duly approved by the Drug Control Authority. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs,innovative scientific manpower, strength of national laboratories and an increasing balance oftrade. The Pharmaceutical Industry, with its rich scientific talents and research capabilities,supported by Intellectual Property Protection regime is well set to take on the internationalmarket.
http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/pharmaceutical-finished-formulations.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/pharmaceutical-finished-formulations.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/pharmaceutical-finished-formulations.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/future-prospects.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/future-prospects.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/future-prospects.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/future-prospects.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/pharmaceutical-finished-formulations.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/

7/31/2019 ST REPORT 11

3/23

Why India?

Competent workforce: India has a pool of personnel with high managerial and technicalcompetence as also skilled workforce. It has an educated work force and English is commonlyused. Professional services are easily available.

Cost-effective chemical synthesis: Its track record of development, particularly in the area ofimproved cost-beneficial chemical synthesis for various drug molecules is excellent. It providesa wide variety of bulk drugs and exports sophisticated bulk drugs.

Legal & Financial Framework: India has a 53 year old democracyand hence has a solid legalframework and strong financial markets. There is already an established international industryand business community.

Information & Technology: It has a good network of world-class educational institutions andestablished strengths in Information Technology.

Globalisation: The country is committed to a free market economy and globalization. Above all,it has a 70 million middle class market, which is continuously growing.

Consolidation: For the first time in many years, the international pharmaceutical industry isfinding great opportunities in India. The process of consolidation, which has become ageneralized phenomenon in the world pharmaceutical industry, has started taking place in India.

Steps to strengthen the Industry

Indian companies need to attain the right product-mix for sustained future growth. Core

competencies will play an important role in determining the future of many Indianpharmaceutical companies in the post product-patent regime after 2005. Indian companies, in an

effort to consolidate their position, will have to increasingly look at merger and acquisition

options of either companies or products. This would help them to offset loss of new product

options, improve their R&D efforts and improve distribution to penetrate markets.

Research and development has always taken the back seat amongst Indian pharmaceutical

companies. In order to stay competitive in the future, Indian companies will have to refocus and

invest heavily in R&D.

The Indian pharmaceutical industry also needs to take advantage of the recent advances in

biotechnology and information technology. The future of the industry will be determined by how

well it markets its products to several regions and distributes risks, its forward and backward

integration capabilities, its R&D, its consolidation through mergers and acquisitions, co-

marketing and licensing agreements.

7/31/2019 ST REPORT 11

4/23

The Indian pharmaceutical industry is highly regulated. The Government controls prices of alarge number of bulk drugs and formulations. Profit margins of players vary widely in bothdomestic and export sales due to many factors.

Domestic Trade of India Pharma Industry

More than 85% of the formulations produced in the country are sold in the domestic market.India is largely self-sufficient in case of formulations. Some life saving, new generation under-patent formulations continue to be imported, especially by MNCs, which then market them inIndia. Overall, the size of the domestic formulations market is around Rs160bn and it is growingat 10% p.a.

Exports of Indian Pharmaceuticals

Over 60% of Indias bulk drug production is exported. The balance is sold locally to other

formulators. Indias pharmaceutical exports are to the tune of Rs87bn, of which formulations

contribute nearly 55% and the rest 45% comes from bulk drugs. In financial year 200, exportsgrew by 21%. Indias pharmaceuticals imports were to the tune of Rs20.3bn in FY2001. Imports

have registered a CAGR of only 2% in the past 5 years. Import of bulk drugs have slowed down

in the recent years.

The exports of Pharmaceuticals during the year 1998-97 were Rs 49780 million. From a meager

Rs 46 crores worth of Pharmaceuticals, Drugs and Fine Chemicals exports in 1980-81,

pharmaceutical exports has risen to approximately Rs 6152 Crores (Prov.1998-99), a rise of

11.91% against the last year exports. Amongst the total exports of India, the percentage share of

Drugs, Pharmaceuticals and Fine Chemicals during April-October (2000-2001) was 4.1%, an

increase of 7%.

Research & Development is the key to the future of pharmaceutical industry. The pharmaceutical

advances for considerable improvement in life expectancy and health all over the world are the result of

a steadily increasing investment in research. There is considerable scope for collaborative R & D in India.

India can offer several strengths to the international R & D community. These strengths relate to

availability of excellent scientific talents who can develop combinatorial chemistry, new synthetic

molecules and plant derived candidate drugs.

R & D in the pharmaceutical industry in India is critical to find answers for some of the diseases peculiar

to a tropical country like India and also for finding solutions for unmet medical needs. Industrial R & D

groups can carry out limited primary screening to identify lead molecules or even candidate drugs for

further in vivo screening, pre-clinical pharmacology, toxicology, animal and human pharmacokinetics

and metabolic studies before taking them up for human trials. In such collaborations, harmonized

standards of screening can be assured following established good laboratory practices.

The R & D expenditure by the Indian pharmaceutical industry is around 1.9% of the industrys turnover.

7/31/2019 ST REPORT 11

5/23

This obviously, is very low when compared to the investment on R & D by foreign research-based

pharma companies. They spend 10 - 16% of the turnover on R & D. However, now that India is entering

into the Patent protection area, many companies are spending relatively more on R & D. When it comes

to clinical evaluation at the time of multi-center trials, India would provide a strong base considering the

real availability of clinical materials in diverse therapeutic areas. Such active collaboration will be

mutually beneficial to both partners. According to a survey by the Pharmaceutical Outsourcing

Management Association and Bio/Pharmaceutical Outsourcing Report, pharmaceutical companies are

utilizing substantially the services of Contract Research Organizations (CROs).

Indian Pharmaceutical Industry, with its rich scientific talents, provides cost-effective clinical trial

research. It has an excellent record of development of improved, cost-beneficial chemical syntheses for

various drug molecules. Some MNCs are already sourcing these services from their Indian affiliates.

The Pharmaceutical and Biotechnology Industry is eligible for weight deduction for R&D expense upto

150%. These R&D companies will also enjoy tax holiday for 10 years. A promotional research and

development fund of Rs.150 crores is set up by the Government to promote research and development

in the pharmaceuticals sector.

hePharmaceutical industryinIndiais the world's third-largest in terms of volume and stands 14th in

terms of value.[1]According to Department of Pharmaceuticals,Ministry of Chemicals and Fertilizers, the

total turnover of India's pharmaceuticals industry between 2008 and September 2009 was US$21.04

billion.[2]While the domestic market was worth US$12.26 billion. Sale of all types of medicines in the

country is expected to reach around US$19.22 billion by 2012. Exports of pharmaceuticals products from

India increased from US$6.23 billion in 2006-07 to US$8.7 billion in 2008-09 a combined annual growth

rate of 21.25%.[2]According toPricewaterhouseCoopers(PWC) in 2010, India joined among the league

of top 10 global pharmaceuticals markets in terms of sales by 2020 with value reaching US$50 billion.[3]

Products

Gufic Biosciences has been known for its products in the area of Pharma, Herbal/Ayurvedic, Consumer

Products and Personal Hygiene Products.

Pharma Products : Ridol Tablets, Vipro-Fe Syrup, Zad-G and Eben Tablets & Suspension. Products

successfully developed and marketed in the recent years are Optifer Capsules, Flabone Chewable

Tablets, Aquadil-P Syrup, Nucart-OA Tablets, Rabol Tablets, Rabol-D Capsules, Menogia Tablets andInjection, Menogia-MF Tablets, Tocolyte Tablets and Injection, Tocolyte-SR Tablets, Prodox

Tablets/Dispersible Tablets and Dry Syrup.

Herbal/Ayurvedic Products : Sallaki Tablets, Sallaki Ointment, Imunocin Tablets and Syrup, Eugynin-L

Tablets, Aswal Plus Tablets, Kofend Syrup.

Consumer Products : Stretch Nil Lotion, Roll-On Cold Rub Oil, Care Ointment and Cream.

Personal Hygiene Products : Shapers and Actislim Sanitary Napkins
http://en.wikipedia.org/wiki/Pharmaceutical_industryhttp://en.wikipedia.org/wiki/Pharmaceutical_industryhttp://en.wikipedia.org/wiki/Pharmaceutical_industryhttp://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-et-0http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-et-0http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-et-0http://en.wikipedia.org/wiki/Ministry_of_Chemicals_and_Fertilizers_%28India%29http://en.wikipedia.org/wiki/Ministry_of_Chemicals_and_Fertilizers_%28India%29http://en.wikipedia.org/wiki/Ministry_of_Chemicals_and_Fertilizers_%28India%29http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/PricewaterhouseCoopershttp://en.wikipedia.org/wiki/PricewaterhouseCoopershttp://en.wikipedia.org/wiki/PricewaterhouseCoopershttp://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-pwc-2http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-pwc-2http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-pwc-2http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-pwc-2http://en.wikipedia.org/wiki/PricewaterhouseCoopershttp://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-cci-1http://en.wikipedia.org/wiki/Ministry_of_Chemicals_and_Fertilizers_%28India%29http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India#cite_note-et-0http://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Pharmaceutical_industry

7/31/2019 ST REPORT 11

6/23

The Centre comprises of four main functional areas viz., Formulation Development, Analytical

Development, Packaging Development and Documentation. A unique integrated approach has been

adopted; wherein Formulation Development work is actively supported by Analytical Development and

Packaging Development functions, eventually leading to Documentation.

Gufic R&D Centre occupies an area of about 6000 sq.ft. and is equipped with sophisticated lab/pilot

scale machines to simulate production conditions for development of all dosage forms e.g. Tablets,

Capsules, Dry Syrups, Dispersible Tablets, Vaginal Tablets, Ointments, Creams, Gels, Liquid Syrups,

Suspensions, Emulsions, Lotions, Solid and Liquid Injectables, etc.

The Formulation Development labs have been designed to include both Lab scale development work as

well as Pilot scale development

work facilities. The lab scale facilities is equipped for development of all types of conventional

pharmaceutical dosage forms. While the pilot scale up labs have been equipped to simulate conditions

similar to that of production by use of pilot scale prototype equipments and machines such as Mass

mixer, Double cone blender, Sifter, Multimill, Planetary mixer, Fluid Bed Drier, Tray Drier, 16 Station

Rotary Tablet compression machine, Colloid Mill, Coating Pan, Capsule filling machine, Ointment/Cream

filling and crimping machine, Ampoule/Vial filling and sealing machine, ROPP Cap Sealing Machine,

Filtration Units for Oral Liquids and for Sterile Preparations, Laminar Flow Bench, Blister and Foil Packing

machine. The products under development are subjected to accelerated stability study conditions using

Incubators/Ovens set at various temperature and humidity, as per ICH guidelines.

The Analytical Development labs support Formulation Development activity by developing New

methods for New molecules and New formulations, New stability indicating Test procedures and

carrying out analysis of accelerated stability studies samples. The analytical development lab has

Modern Instruments such as Binary Gradient High Pressure Liquid Chromatograph, UV-Visible

Spectrophotometer, Gas Chromatograph, Potentiometric Autotitrator, Polarimeter, Refractometer,

Brookfield Viscometer, 6-Station Dissolution Rate Apparatus, etc. The in-house Microbiological Testing

for Antibiotic Assay, Sterility, Microbial Count, etc., is carried out with the help of equipments such as

B.O.D. Incubator, Antibiotic Assay Zone Reader, Laminar Flow Bench, Autoclave etc.

The Packaging Development Lab is equipped with equipments such as Vibration Tester, Drop Tester,

Tensile Strength Tester, Substance Indicator for GSM measurements, Cobb Tester and Bursting Strength

Tester to develop and evaluate the packaging from immediate container/closure stage to the final

shipper pack stage.

The Centre subscribes to Indian and International Scientific Journals for in-house reference work. The

Centre is manned by qualified and experienced Scientists from the field of Pharmaceutical Sciences,

Analytical Chemistry, Microbiology, and Packaging Technology.

R &D functions

New Pharma Products Formulation Development Innovative Dosage Form Development New Drug Delivery Systems viz., Sustained

Release Products

7/31/2019 ST REPORT 11

7/23

Newer Platform Technology Development viz.,Colon Targeted Products

Analytical Method Development and Standardisationof Analytical Test Procedures

Packaging Development

Product Development for Exports Novel Herbal based Product Development

Therapeutic segments

Anti-infectives Orthopaedic Disorders Gynaecological Disorders Gastrointestinal Disorders

http://www.guficbio.com/rd/funcations.htm

http://www.guficbio.com/rd/therapeutic.htm

http://www.guficbio.com/rd/products.htm

seeds

With the expertise created in the field of agriculture, over the years, along with the right type ofresearch, Gufic has entered into hybrid vegetable seeds. Gufic seeds deals in all major vegetableseeds namely, tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd,

bitter gourd, ridge gourd, brinjal, cucumber and watermelon. It is bringing out varieties/hybridsas per the local demands and preferences for particular characteristics in a crop.Towards this goal, Gufic seeds has already made arrangements with world class breeders andcompanies to get excellent seed material for development and promotions. Company commandsthe association of skilled, accomplished and seasoned professionals in research, production andmarketing and we shall be striving to bring to you the best of hybrids and varieties to suitspecific requirements on continues basis.

Manufacturing

Presentation

VialVialVialVial / TabletVial / Tablet
http://www.guficbio.com/rd/funcations.htmhttp://www.guficbio.com/rd/funcations.htmhttp://www.guficbio.com/rd/therapeutic.htmhttp://www.guficbio.com/rd/therapeutic.htmhttp://www.guficbio.com/rd/products.htmhttp://www.guficbio.com/rd/products.htmhttp://www.guficbio.com/rd/products.htmhttp://www.guficbio.com/rd/therapeutic.htmhttp://www.guficbio.com/rd/funcations.htm

7/31/2019 ST REPORT 11

8/23

7/31/2019 ST REPORT 11

9/23

CapsulesInjectionTabletTabletTablet

TabletTabletInjection

Molecule Presentation

Vial

Vial

Vial

Vial / TabletVial / Tablet

Vial

Vial

Vial / Tablet

Vial / Tablet

Vial

Vial

Vial

Vial

Vial

Vial

Vial

Vial

Vial

Vial

Vial

Vial

Vial

VialVial

Vial

Vial

Vial

Vial

Vial / Tablet

7/31/2019 ST REPORT 11

10/23

Vial

Vial

Vial

Vial

Vial

Tablet

Tablet

Tablet

Tablet

Tablet

Tablet

Tablet

Tablet

Tablet

TabletTablet

Tablet

Tablet

Tablet

Tablet

Tablet

Tablet

Capsules

Injection

TabletTablet

Tablet

Tablet

Tablet

Injection

Molecule

Follicle Stimulating HormoneMenotropinHuman Chorionic GonadotrophinRabeprazole SodiumOmeprazole SodiumPantoprazole SodiumEsomeprazole Sodium

7/31/2019 ST REPORT 11

11/23

Isoxsuprine HydrochlorideTranexamic acidPiperacillin + Tazobactam SodiumCeftriaxone SodiumAzithromycin

Amphotericin-BDobutamine HydrochlorideSodium NiroprussideCefpirome SulphateSulbactum + Cefoperazone SodiumMeropenen TrihydrateTeicoplaninVancomycin HydrochlorideKetoprofenAcyclovir sodiumHaemocoagulase

Zoledronic acidUrokinaseStreptokinaseIbandronate Monosodium MonohydrateHydrocortisone Sodium SuccinateParecoxibSodium HyaluronateFilgrastim (rhG-CSF)ImipenamSilastatinGatifloxacinCandesartanIndapamide SRTrimetazidine MRFelodipine ERPerindoprilClopidogrelSimvastatin MRRozuvastatinGliclazide MRMetformin MRGlimepiridePioglitazoneSodium ValproateNA Valproate + Valporic AcidCarbamazepine CRRespiridonSertralineZiprasidoneZiprasidone

7/31/2019 ST REPORT 11

12/23

Itopride HClTegaserod MeleateBalsalazide SodiumCefprodoxime ProxetilLevofloxacin

ParacetomolStrength

75 / 150 I.U.75 / 150 I.U.500020 ng40 mg40 mg40 mg5 mg

4.5 gm125 / 600 mg100 / 500 mg50 mg250 mg50 mg1 gm1 gm500 mg / 1 gm400 mg500 mg100 mg250 mg1 ml

2,50,0007,50,000 / 15,00,0002 ml

40 mg

1 ml500 mg500 mg200 / 300 / 400 mg8 / 16 mg1.5 mg35 mg2.5 / 5 / 10 mg

7/31/2019 ST REPORT 11

13/23

2 / 4 mg75 mg60 mg5 / 10 / 20 mg30 / 60 mg

850 mg1 / 2 / 3 mg15 / 30 mg

20 / 40 / 60 mg20 mg50 mg

6 mg750 mg100 / 200 mg500 mg

Follicle Stimulating HormoneMenotropinHuman Chorionic GonadotrophinRabeprazole SodiumOmeprazole SodiumPantoprazole SodiumEsomeprazole SodiumIsoxsuprine HydrochlorideTranexamic acidPiperacillin + Tazobactam SodiumCeftriaxone SodiumAzithromycinAmphotericin-BDobutamine HydrochlorideSodium NiroprussideCefpirome SulphateSulbactum + Cefoperazone SodiumMeropenen TrihydrateTeicoplaninVancomycin HydrochlorideKetoprofenAcyclovir sodiumHaemocoagulaseZoledronic acid

7/31/2019 ST REPORT 11

14/23

UrokinaseStreptokinaseIbandronate Monosodium MonohydrateHydrocortisone Sodium SuccinateParecoxib

Sodium HyaluronateFilgrastim (rhG-CSF)ImipenamSilastatinGatifloxacinCandesartanIndapamide SRTrimetazidine MRFelodipine ERPerindoprilClopidogrel

Simvastatin MRRozuvastatinGliclazide MRMetformin MRGlimepiridePioglitazoneSodium ValproateNA Valproate + Valporic AcidCarbamazepine CRRespiridonSertralineZiprasidoneZiprasidoneItopride HClTegaserod MeleateBalsalazide SodiumCefprodoxime ProxetilLevofloxacinParacetomolStrength

75 / 150 I.U.75 / 150 I.U.500020 ng40 mg40 mg40 mg5 mg

7/31/2019 ST REPORT 11

15/23

4.5 gm125 / 600 mg100 / 500 mg50 mg250 mg

50 mg1 gm1 gm500 mg / 1 gm400 mg500 mg100 mg250 mg1 ml

2,50,000

7,50,000 / 15,00,0002 ml

40 mg

1 ml500 mg500 mg200 / 300 / 400 mg8 / 16 mg1.5 mg35 mg2.5 / 5 / 10 mg2 / 4 mg75 mg60 mg5 / 10 / 20 mg30 / 60 mg850 mg1 / 2 / 3 mg15 / 30 mg

20 / 40 / 60 mg20 mg50 mg6 mg

7/31/2019 ST REPORT 11

16/23

750 mg100 / 200 mg500 mg

Gufic Bioscience Ltd.Address N.H. NO. 8, NEAR GRID, KABILPORE, Navsari - 396424, Gujarat, India Phone No

91-2637-258077/258078 Contact Person MR. VIMAL KUMAR SOLANKI Mobile

+91942692420

ompany Name Gufic Biosciences LimitedContact Person Dr.M.G.Dhapalapur Address Old Sankar Jyot

School Building, 2nd,3rd,4th Floor, Above Bank Of Maharasthra, Next to Shopper's Stop, Andheri(W)

Mumbai, Maharashtra, India. Zip / Postal Code 400 058 Telephone +91 - 22 - 67261009 ,09324209193

FaxEmailClick here to email us Websitewww.guficbio.com Company Info Factory:

Kabilpure

Navsari

Gujarat - 396 424

PH: 91-2637-58077, 58078

FAX; 91-2637-58280

E-MAIL: [email protected]

Contact:

Dr.M.G.Dhapalapur(Vice-President)

Products

Gufic Biosciences has been known for its products in the area of Pharma, Herbal/Ayurvedic, Consumer

Products and Personal Hygiene Products.

Pharma Products : Ridol Tablets, Vipro-Fe Syrup, Zad-G and Eben Tablets & Suspension. Products

successfully developed and marketed in the recent years are Optifer Capsules, Flabone Chewable

Tablets, Aquadil-P Syrup, Nucart-OA Tablets, Rabol Tablets, Rabol-D Capsules, Menogia Tablets and

Injection, Menogia-MF Tablets, Tocolyte Tablets and Injection, Tocolyte-SR Tablets, ProdoxTablets/Dispersible Tablets and Dry Syrup.

Herbal/Ayurvedic Products : Sallaki Tablets, Sallaki Ointment, Imunocin Tablets and Syrup, Eugynin-L

Tablets, Aswal Plus Tablets, Kofend Syrup.

Consumer Products : Stretch Nil Lotion, Roll-On Cold Rub Oil, Care Ointment and Cream.

Personal Hygiene Products : Shapers and Actislim Sanitary Napkins
http://www.guficbio.com/http://www.guficbio.com/http://www.guficbio.com/

7/31/2019 ST REPORT 11

17/23

The Gufic R&D Centre - Technology Development Dept., is a state-of-the-art researchlaboratory. The centre commenced functioning in July 1995 and has been designed with a viewto be fully dedicated towards a newer concept of 'Total Product Development'. It was created tomeet the challenges of the emerging global market, as well as the domestic market requirement,by developing New Pharmaceutical Products, New Drug Delivery Systems (NDDS), New

Platform Technologies which will enhance the quality of life, globally.

R& D functions

New Pharma Products Formulation Development Innovative Dosage Form Development New Drug Delivery Systems viz., Sustained

Release Products Newer Platform Technology Development viz.,

Colon Targeted Products Analytical Method Development and Standardisation

of Analytical Test Procedures Packaging Development Product Development for Exports Novel Herbal based Product Development

Gufic Biosciences is a Private Sector Organisation that offers services in Pharmaceuticals/ BioTech/

Research with An nual Total Turnover of 10-100 Crs and with Employee Strength of 501-1000.

http://info.shine.com/company/Gufic-Biosciences-Ltd/4148.aspx

health

Healthcare and personal hygiene are evolving like never before. It's to match steps with changinglifestyles; eating habits; work culture; environmental changes and associated ailments or needs.The most reassuring fact about today's life is that, though after a fifty-year-long slumber, peopleare going back to nature. Natural foods, natural cosmetics, natural therapies, etc. Gufic believes,it's a welcome change.

Gufic, with one of the finest Tissue Culture labs in India, along with a sophisticated R&D Centerand a robust infrastructure, has always relied on nature to make good whatever mankind has lostin modernization. Gufic's vision is to grow into a global Bioscience major with its inherent value

7/31/2019 ST REPORT 11

18/23

systems that adheres to honesty in every action. Every step is taken towards enhancing thequality of human life back to the green future

Bio tech

Gufic started its plant biotechnology operation three years ago to produce and supply the high yielding and eliteplanting material of medicinal and other herbal plants using tissue culture techniques. The first biotechnology

product was bixa, a source of natural food colour, for which the company has buy back arrangement with the

farmers.

Facility

This company has a well developed tissue culture facility for production of 5 million plants per annum. The

production unit is made by state of the art technology with six growth rooms, which can house 160000 culture

bottles at a time. In the inoculation area, 30 persons can work in one shift. The air-conditioning and air handling

system incorporates 5 micron and 0.5 micron filters and are designed for class 10,000 and class 100,000 as per us

federal standards 209b. The work stations are however class 100.

Green house

The company has two green houses of 800 square meters with evaporative cooling, misting and shading

equipment for hardening of tissue culture plants.

In addition the company has shade houses for hardening of plants at 4 loacations.

Product

This facility is being used for production of banana, potato,

sugarcane, date palm, jatropha for indian market.

The company has developed in-house, on line real time

computer software for forward planning of production schedule

to meet market demands as well as monitoring daily

production schedule and generating mis reports.

The company has highly motivated ph.d. and m.sc. personnel

who man our production facility. They are supported by highly

enthusiastic and hardworking staff who are ever willing to give

better productivity both in qualitative and quantitative terms.

Bixa

One of the major crops in which Gufic has interest is bixa, a source of natural food colour. The company proposesto have a buy-back for 500 acres of bixa plantation for which the tissue cultured plants are supplied to farmers

under a buy-back agreement.

Bixa tips

Soil: Porous soils with good water leaching

capacity are the best

7/31/2019 ST REPORT 11

19/23

Water logging soils like paddy fields are not recommended

In slight alkaline soil, bixa can be planted with high amount of organic compost and FYM

Seeds

With the expertise created in the field of agriculture, over the years, along with the right type of

research, Gufic has entered into hybrid vegetable seeds. Gufic seeds deals in all major vegetable seeds

namely, tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd,

ridge gourd, brinjal, cucumber and watermelon. It is bringing out varieties/hybrids as per the local

demands and preferences for particular characteristics in a crop.

Towards this goal, Gufic seeds has already made arrangements with world class breeders and companies

to get excellent seed material for development and promotions. Company commands the association of

skilled, accomplished and seasoned professionals in research, production and marketing and we shall be

striving to bring to you the best of hybrids and varieties to suit specific requirements on continues basis.

MOLECULE PACKING NAME INDICATION

TABLETS

Cefixime 100mg 10's EXIM 100 ANTIBACTERIAL

Cefixime 200mg 10's EXIM 200 ANTIBACTERIAL

Gatifloxacin 400mg. 10's GUFIGAT ANTIBACTERIAL

Levofloxacin 500mg. 5's GUFILOX 500 ANTIBACTERIAL

Norfloxacin 400mg. 10's GYROCIDE-400 ANTIBACTERIAL

Ciprofloxacin 250mg 10 ZIPCIN 250 ANTIBACTERIAL

Ciprofloxacin 500mg 10 ZIPCIN 500 ANTIBACTERIAL

Nimuslide 100mg. 10's MOLSLIDE ANTIINFLAMATORY

Nimuslide 100mg

+ Paracetamol 500mg. 10's MOLSLIDE-P ANTIINFLAMATORY

Diclo. 50mg + Para 500mg +

Chlorzoxazone 250mg. 10's MOL PLUS ANTIINFLAMATORY

Aclofenac + Paracetamol 10's MOLACE ANTIINFLAMATORY

Aclofenac + Paracetamol

+ Serratiopeptidase 10's MOLACE S ANTIINFLAMATORY

Diclofenac 50mg

+ Serratiopeptidase 10mg. 10's GUFISERA D ANTIINFLAMATORY

Cetrizine 10mg. 10's GITZEN ANTIALLERGIC

Levocitrazine 5mg. 10's GITZEN L ANTIALLERGIC

7/31/2019 ST REPORT 11

20/23

Levocitrazine 5mg

+ Amroxyl 60mg. 10's GITZEN LA ANTIALLERGIC

Levocitrazine 5mg

+ Amroxyl 60mg +

Para 500mg + Phenyl 2.5mg. 10's GITZEN PLUS ANTIALLERGIC

Pentaprazole 40mg. 10's GEPAN ANTIULCERANT

Pentaprazole 40mg.

+ Domperidone 10mg. 10's GEPAN D ANTIULCERANT

Ranitidine 150mg. 10's RIDCER 150 ANTIULCERANT

Ranitidine 150mg.

+ Domperidon 10mg. 10's RIDCER D ANTIULCERANT

Albendazole 400mg. 1's GUFIBEND WORMICIDAL

Paracetamol 500mg. 10's MOL

Paracetamol + Diclofenac 10's MOL-D

Cefadroxil 125mg. 10's GUFIDROX 125



Ciprofloxacin

Hydrochloride 250mg. 10's ZIPCIN 250

Ciprofloxacin

Hydrochloride 500mg. 10's ZIPCIN 500

Ciprofloxacin 500mg

+Tinidazole 600mg. 10's ZIPCIN TZ

Co-trimoxazole DS 10's COTROX DS

Co-trimoxazole SS 10's COTROX SS

Serratiopeptidase 10mg. 10's GUFISERA

Mebendazole 100mg. 10X6 EBEN

Clotrimazole 100mg. 6's CANDO V 100 ANTI FUNGAL

Clotrimazole 200mg. 3's CANDO V 200 ANTI FUNGAL

capsules

Omperazole 20mg. 10's OPEL ANTIULCERENT

7/31/2019 ST REPORT 11

21/23

Omprozole 20mg

+ Domperidone 10mg. 10's OPEL-D ANTIULCERENT

Ashwagadha 100mg

+ Kaunchbeej 100mg +

Shatavari 100mg +

Arjuna 100mg +

Kali Musli 40mg +

Kshir Vidari 25mg +

Varahikand 22mg +

Kokilaksha 12mg +

Jatipatri 9mg +

Akalkara 8mg +

Shilajit 50mg

+ Yashad Bhasma 25mg 10's ONERGY VIGOUR

Enzyme Cap. 10's GUFIZYME

Cephalexin 250mg. 10's SUXIL 250 ANTIBIOTIC

Cephalexin 500mg. 10's SUXIL 500 ANTIBIOTIC

Syrups Diphenhy 14.08

+ Amm Cit 0.138 +

Sod. Cit 57.03

+ Menthol 1.14mg +

Alcohol 5% v/v 100ml GUFIDRYL COUGH SRYUP

Terbutaline Sulphate + Bromhexine Hydrochloride +

Guaiphenesin Syrup 100ml. BROMAX COUGH SRYUP C. P. Mateate + Ammonium Chloride +

Sodium Citrate Syrup 100ml. GEDEX COUGH SRYUP Acetaminophen 125mg + Pseudoephedrine 15mg +

Dextromethor 60ML ROLLON COUGH &COLD Chlorpheniramine Maleate + Phenyl Propanolaminc

HCL 12.5mg (with carton) 60ml. G COLD COUGH &COLD CPM + PPH + Paracetamol 125mg (with carton)

60ml. G COLD PLUS COUGH &COLD Levocetirizine Dihydrochloride 2.5mg. 30ml. GITZEN L ANTI ALLERGY

Levocetirizine Dihydrochloride 2.5mg. +

Ambroxol HCI 15mg. 30ml. GITZEN LA ANTI ALLERGY Cefixime Syrup 15gm/30ml. 30ml. EXIM

ANTIBITOIC Cephalexin Dry Syrup 125mg/5ml 30ML SUXIL ANTIBITOIC Paracetamol Syrup 60ML. MOL

ANTIPYRATIC Nimesulide + Paracetamol 60ml. MOLSLIDE P ANTIPYRATIC Ofloxacin 30ml. NIDIL

7/31/2019 ST REPORT 11

22/23

ANTIBACTERIAL Ofloxacin + Tinidazole 30ml. NIDIL TZ ANTIBACTERIAL Iron Syrup 200ml. GUFIRON IRON

B Complex Syrup 200ml. GUFIBION BCOMPLEX Albendazole 200mg/5ml. 10ml GUFIBEND WORMICIDAL

Antacid Syrup 170ml. GUFIGEL MPS ANTIACID Enzyme Syrup 200ML GUFIZYME ENZYME Cefadroxil Dry

Syrup 125mg/5ml 30ml GUFIDROX Mebendazole Dry Syrup 125mg/5ml 30ml EBEN

OINTMENTS / CREAMS & GELS

Clotrimazole cream & Beclomethasone

Diprpionate 15gm CANDO - B ANTI FUNGAL Clotrimazole Cream 15gm CANDO ANTI FUNGAL Pioviodine

Ointment 15gm. GUFIDINE Silver Sulphadiazine USP 1%w/w Antiseptic

Cream 15gm. SILVEREX Nimesulide Gel 30gm. MOLSLIDE GEL PAIN RELIVER Nimesulide 1.00%+Methyl

Salicylate 10.3%+

Menthol 5.15% 30gm. MOLSLIDE PLUS GEL PAIN RELIVER Betamethasone 0.643 + Gentamicin +

Tolnaftate + Idochlorohydroxy quinoline 5gm. GUFIDERM PAIN RELIVER Betamethasone Valerate 20GM

BETANE PAIN RELIVER Betamethasone Valerate + Neomycin 20GM BETANE-N ANTI BACTRIAL Gama

Benzene Hexacl 1% w/v Ointment 15gm GAB SCABICIDAL Pioviodine Ointment 15gm GUFIDINE

ANTIMICROBIAL Silver Sulfadiazine & Chlorhexidine

Gluconate Cream 15gm. GUFIREX SS BURNS Diclofenac Diethylammonium 1.16 gm

(eqv. to Diclo Sod. 1% per 100gm) 30gm. GENEFEC GEL PAIN RELIVER Linseed Oil 3.0%, Diclofenac

Diethylamine 1.16%,

Methyl Salicylate 10.0% Menthol 5.0%,

Benzyl Alcohol 1.0% 30gm. GENEFEC PLUS GEL PAIN RELIVER

LOTIONS

Gama Benzene Hexacl 1% w/v Lotion 100ml. GAB LOTION SCABICIDAL

INJECTIONS

Amikacin 100mg Vial GUFIMIKA 100MG Amikacin 500mg Vial GUFIMIKA 500MG Omeprazole 40mg.

Vial OPEL ANTI ULCERNT Pentaprazole 40mg. Vial G PAN ANTI ULCERNT Ranitidine 2ml. Ampoule

RIDCER ANTI ULCERNT Paracetamol 2ml. Ampoule MOL ANTI PYRETIC Metaclopramide 2ml. Ampoule

TOMID Hydrocortisone Sodium Succinate Injection 100mg. Vial COTRISONE Diclofenac 3ml. Ampoule

GEFENEC ANTIINFLAMATORY Ceftriaxone 1mg (With water for injection 10ml) Vial GUFITROX 1GM.

ANTIBACTERIAL Ceftriaxone 250mg (With water for injection 3ml) Vial GUFITROX 250 Cefotaxim 1gm

(With water for injection) Vial GUFITAX 1GM. Cefotaxim 250gm (With water for injection) Vial GUFITAX

250

OTHERS Clotrimazole Dusting Powder 75gm CANDO D.P. ANTI FUNGAL Oral Rehydration Salts ORS

(Orange Flavour) 28.5gm GETRAL ORS ORS

http://www.guficbio.com/html/generic.html
http://www.guficbio.com/html/generic.htmlhttp://www.guficbio.com/html/generic.htmlhttp://www.guficbio.com/html/generic.html

7/31/2019 ST REPORT 11

23/23

http://www.moneycontrol.com/annual-report/guficbiosciences/raw-

materials/GB04#GB0

Capital Structure Period Instrument --- CAPITAL (Rs. cr) --- - P A I D U P - From To Authorised Issued Shares

(nos) Face Value Capital 20102011Equity Share107.747735000017.7420092010Equity

Share107.747735000017.7420082009Equity Share107.747735000017.7420072008Equity





Share10.9900000100.9
http://www.moneycontrol.com/annual-report/guficbiosciences/raw-materials/GB04#GB0http://www.moneycontrol.com/annual-report/guficbiosciences/raw-materials/GB04#GB0http://www.moneycontrol.com/annual-report/guficbiosciences/raw-materials/GB04#GB0http://www.moneycontrol.com/annual-report/guficbiosciences/raw-materials/GB04#GB0http://www.moneycontrol.com/annual-report/guficbiosciences/raw-materials/GB04#GB0

st report 11

Documents